3rd Symposium on Infectious Diseases in the Immunocompromised Host

项目总结 在美国，越来越多的人患有免疫缺陷。最新进展 移植技术和癌症治疗，提高这些患者的存活率，以及发展 治疗自身免疫性疾病的新药物促进了这一群体的增长。在美国，它是 据估计，截至目前，超过34万人生活在功能正常的移植固体器官(SOT)中 2016年，每年进行的新的造血细胞移植和SOT超过5.6万例。感染仍然是一种 这是这一高度易感人群发病和死亡的主要原因。此外，这些人是 通常受到病原体的影响，而这些病原体很少在健康人中引起疾病。高质量的患者护理和养育 协作、跨学科的研究，以增加我们对这些感染的了解，并推动发展 新的治疗和预防选择，是改善这些患者预后的关键优先事项。 专注于免疫功能低下患者中的传染病的会议对 在实地促进及时讨论和有效传播思想，但这样的论坛很少。 为了弥合这一差距，弗雷德·哈钦森癌症研究中心的传染病科学项目 于2016年发起了关于免疫受损宿主中的传染病研讨会。这项活动有 吸引了知名演讲者和传染病领域人士的浓厚兴趣，使我们能够 在第二年，将研讨会扩大到为期两天的活动，有176人参加。我们的2019年研讨会计划 将由该领域的思想领袖以及职业生涯早期的调查人员进行演讲，三个主旨 由专家小组领导的两次互动案例讨论，以及为学员提供的机会，包括 演讲和两次海报会议。我们2019年研讨会计划中涉及的新主题将包括： 艰难梭菌，不成比例地影响免疫功能低下的患者，以及抗菌药 管家的职责。我们2017年研讨会的成功要素将保持不变，包括以下内容 主题：呼吸道病毒病，巨细胞病毒，真菌病，微生物组，和免疫治疗。 这次活动的一个鲜明和创新的特点是我们的重点是支持学员的出席和参与， 特别是妇女和代表人数不足的群体的个人。我们的目标是通过以下方式延续这一传统 提供大量的实习生津贴，并组织我们的计划以促进有意义的互动 在今天该领域的领导者和未来几十年将为之做出贡献的后起之秀之间。我们的目标是 在免疫受损的宿主中促进关于传染病的富有成效的讨论，推动在 目前该领域的问题，以及促进传播将改善临床实践的知识 在全国各地。这次会议通过让职业生涯初期的实习生接触到以下内容来加强培训渠道 诱人的领域，同时支持学员(包括那些在我们的NIH支持的T32培训计划中的学员)磨练 他们的技能和获得他们启动独立职业所需的知名度。

PROJECT SUMMARY Within the United States, a growing proportion of the population is immunocompromised. Advances in transplantation techniques and cancer treatments, increased survival of these patients, and the development of novel agents to treat autoimmune diseases have contributed to the increase in this population. In the US, it is estimated that more than 340,000 people were living with a functioning transplanted solid organ (SOT) as of 2016, and over 56,000 new hematopoietic cell transplants and SOTs are done every year. Infection remains a major cause of morbidity and mortality for this highly susceptible population. Furthermore, these individuals are often affected by pathogens that rarely cause disease in healthy people. High-quality patient care and fostering collaborative, interdisciplinary research to increase our understanding of these infections, and drive development of new options for treatment and prevention, are vital priorities for improving outcomes among these patients. Conferences focused on infectious diseases specifically within immunocompromised patients are crucial for promoting timely discussions and efficient dissemination of ideas within the field, yet few such forums exist. To bridge this gap, the Fred Hutchinson Cancer Research Center's Infectious Disease Sciences Program launched in 2016 the Symposium on Infectious Diseases in the Immunocompromised Host. This event has attracted high-profile speakers and intense interest among those in the infectious diseases field, allowing us to expand the symposium to a two-day event with 176 attendees in the second year. Our 2019 symposium program will feature lectures by thought leaders in the field as well as early-career investigators, three keynote presentations, two interactive case discussions led by expert panels, and opportunities for trainees including presentations and two poster sessions. New topics addressed in our 2019 symposium program will include: Clostridium difficile, which disproportionately affects immunocompromised patients, and antimicrobial stewardship. Successful elements of our 2017 symposium will be maintained, including coverage of the following topics: Respiratory Virus Disease, Cytomegalovirus, Fungal Disease, Microbiome, and Immunotherapy. A distinct and innovative feature of this event is our focus on supporting attendance and participation by trainees, especially by women and individuals from underrepresented groups. We aim to continue this tradition by providing a generous number of trainee stipends and structuring our program to facilitate meaningful interactions between today's leaders in the field and the rising stars who will contribute to it for decades to come. We aim to foster productive discussions on infectious diseases in the immunocompromised host, driving progress on current issues in the field as well as promoting dissemination of knowledge that will improve clinical practice across the country. This conference strengthens the training pipeline by exposing early-career trainees to this enticing field, while supporting trainees (including those in our NIH-supported T32 training program) in honing their skills and gaining the visibility they need to launch independent careers.